0JV0.F iBio, Inc.

Healthcare Biotechnology Frankfurt Exchange
0.6505 EUR
Close of Nov 11, 2026
0.5950 2.62
Market cap
EUR 32.3M
P/E
-
P/B
0.59x
ROE
-38.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is 0JV0.F undervalued?

Graham number

The Graham number of iBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

iBio, Inc. fundamental analysis

No fundamental analysis for iBio, Inc. yet.

iBio, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About iBio, Inc.

iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company's technology platforms include EngageTx that provides a panel of optimized CD3 antibodies that can be paired with tumor-targeting antibodies to generate bispecific T-cell engagers; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology, small binding sites on large…

Full company profile